Edwards Lifesciences Corporation

EW · NYSE · ·

Comparar

105,83 US$+1,7 %cierre 11 nov

Cifras hasta el 30 de septiembre de 2026, del 10-Q presentado el 4 de noviembre de 2026

1W: +3,6 %
1M: +24,1 %

Acciones de Edwards Lifesciences Corporation (EW) — ¿es un buen negocio? — InspectStocks

Edwards Lifesciences Corporation

EW · NYSE · ·

Comparar

105,83 US$+1,7 %cierre 11 nov

Cifras hasta el 30 de septiembre de 2026, del 10-Q presentado el 4 de noviembre de 2026

1W: +3,6 %
1M: +24,1 %

Just reported

Q3 2026 results

From Edwards Lifesciences's results release of 4 de noviembre de 2026; its quarterly report has since been filed.

Revenue
Actual
1,72B US$
+10 % y/y
-1,5 % q/q
Guided
1,67B US$
midpoint
Above guide+2,7 %
EPS, GAAP
Actual
0,53 US$
+6,0 % y/y
+26 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
299,1M US$
-2,6 % y/y
-42 % q/q
Guided
—
No guide given

Company outlook

Q4 2026

Revenue1,67B US$ – 1,75B US$+8,9 % y/y First given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Cómo gana dinero

Catheter-delivered aortic valve replacement72 %
Catheter-delivered mitral and tricuspid valve repair and replacement11 %
Surgical heart valve products16 %

Los porcentajes de ingresos son estimaciones para nine months ended September 30, 2026, no cifras de un informe oficial.

Compite con

Qué vende5

SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.

Mostrar 2 más

SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.

Quién se lo compra3

Hospitals and health systems buy devices directly from Edwards sales teams or through distributors; in the United States, sales are mainly direct.
Hospital purchasing groups and healthcare networks negotiate supplier contracts on behalf of hospitals.
Heart specialists, including cardiac surgeons and interventional cardiologists, use the devices and take part in choosing treatments.

En qué se apoya y qué podría romperlo

De qué depende el negocio

1A large part of the business depends on hospitals adopting catheter-delivered aortic valve replacement and on clinicians choosing Edwards devices.
2Sales depend in part on government and private insurers covering procedures and paying hospitals enough to support their use.
3Some materials and components come from single-source suppliers; switching critical suppliers can require lengthy regulatory review.
4The company relies on clinical studies and regulatory clearances or approvals to bring devices to market and expand their permitted uses.

Qué podría salir mal

1If clinical studies do not show the needed results, or regulators do not approve new devices or uses, Edwards may be unable to sell those products or expand their use.
2Manufacturing, quality, safety, or delivery problems at Edwards or its suppliers could interrupt access to implanted heart valves and other devices.
3If insurers or government health programs restrict coverage or reduce payments, hospitals may buy fewer devices or seek lower prices.

Estados financieros completos →

Sobre Edwards Lifesciences Corporation

Edwards makes devices that replace or repair damaged heart valves. Some are delivered through a catheter, a thin tube passed through a blood vessel, while others are implanted during open-heart surgery. Hospitals and heart specialists use these devices to treat diseases affecting the aortic, mitral, and tricuspid valves.

Sede: Irvine, California, United States
Fundada en: 1958
Empleados: Approximately 16,000 (December 31, 2025, medium)
Cotiza en: New York Stock Exchange
Cierre del ejercicio: December 31

Construido a partir de los propios informes de Edwards Lifesciences Corporation ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.

Just reported

Q3 2026 results

From Edwards Lifesciences's results release of 4 de noviembre de 2026; its quarterly report has since been filed.

Revenue
Actual
1,72B US$
+10 % y/y
-1,5 % q/q
Guided
1,67B US$
midpoint
Above guide+2,7 %
EPS, GAAP
Actual
0,53 US$
+6,0 % y/y
+26 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
299,1M US$
-2,6 % y/y
-42 % q/q
Guided
—
No guide given

Company outlook

Q4 2026

Revenue1,67B US$ – 1,75B US$+8,9 % y/y First given

Keep exploring

The themes Edwards Lifesciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Medical Devices

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

Cómo gana dinero

Catheter-delivered aortic valve replacement72 %
Catheter-delivered mitral and tricuspid valve repair and replacement11 %
Surgical heart valve products16 %

Los porcentajes de ingresos son estimaciones para nine months ended September 30, 2026, no cifras de un informe oficial.

Compite con

Qué vende5

SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.

Mostrar 2 más

SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.

Quién se lo compra3

Hospitals and health systems buy devices directly from Edwards sales teams or through distributors; in the United States, sales are mainly direct.
Hospital purchasing groups and healthcare networks negotiate supplier contracts on behalf of hospitals.
Heart specialists, including cardiac surgeons and interventional cardiologists, use the devices and take part in choosing treatments.

En qué se apoya y qué podría romperlo

De qué depende el negocio

1A large part of the business depends on hospitals adopting catheter-delivered aortic valve replacement and on clinicians choosing Edwards devices.
2Sales depend in part on government and private insurers covering procedures and paying hospitals enough to support their use.
3Some materials and components come from single-source suppliers; switching critical suppliers can require lengthy regulatory review.
4The company relies on clinical studies and regulatory clearances or approvals to bring devices to market and expand their permitted uses.

Qué podría salir mal

1If clinical studies do not show the needed results, or regulators do not approve new devices or uses, Edwards may be unable to sell those products or expand their use.
2Manufacturing, quality, safety, or delivery problems at Edwards or its suppliers could interrupt access to implanted heart valves and other devices.
3If insurers or government health programs restrict coverage or reduce payments, hospitals may buy fewer devices or seek lower prices.

Estados financieros completos →

Sobre Edwards Lifesciences Corporation

Sede: Irvine, California, United States
Fundada en: 1958
Empleados: Approximately 16,000 (December 31, 2025, medium)
Cotiza en: New York Stock Exchange
Cierre del ejercicio: December 31

Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Cómo gana dinero

Compite con

Qué vende5

Quién se lo compra3

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Edwards Lifesciences Corporation

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Medical Devices

Grade rose recently in Healthcare

Cómo gana dinero

Compite con

Qué vende5

Quién se lo compra3

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Edwards Lifesciences Corporation

Keep exploring

The theme it is part of

Highest-graded in Medical Devices

Grade rose recently in Healthcare

Medical devices

Crecimiento y caja — 5 de 5

Tendencia del negocio

Precio de la acción y calificación a lo largo del tiempo